Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) updated on 07-01-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S11771
R43269		 Anderson - SNRI, 2020 Hypospadias, 2nd or 3rd degree 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: SNRI only 1.77 [0.73;4.28] -/-   0/- - -
ref
S11688
R42977		 Furu - Venlafaxine, 2015 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: SNRI only 1.13 [0.54;2.38] 7/2,763   4,526/2,266,875 4,533 2,763
ref
S11693
R76992		 Reis - SNRI (Controls exposed to TCA), 2010 Hypospadias 1st trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No Monotherapy: SNRI only 0.82 [0.29;2.31] C
excluded (control group) 		6/1,351   9/1,662 15 1,351
ref
S11694
R76988		 Reis - SNRI (Controls unexposed, NOS), 2010 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: SNRI only 1.47 [0.54;3.19] 6/1,351   3,198/1,062,190 3,204 1,351
ref
Total 3 studies 1.39 [0.86;2.25] 7,737 4,114
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson - SNRI, 2020Anderson - SNRI, 2020 1.77[0.73; 4.28]--29%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Furu - Venlafaxine, 2015Furu - Venlafaxine, 2015 1.13[0.54; 2.38]4,5332,76342%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Reis - SNRI (Controls unexposed, NOS), 2010Reis - SNRI, 2010 1 1.47[0.54; 3.19]3,2041,35129%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Total (3 studies) I2 = 0% 1.39[0.86; 2.25]7,7374,1140.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.26[0.71; 2.22]7,7374,1140%NAFuru - Venlafaxine, 2015 Reis - SNRI (Controls unexposed, NOS), 2010 2 case control studiescase control studies 1.77[0.73; 4.29]-- -NAAnderson - SNRI, 2020 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.39[0.86; 2.25]7,7374,1140%NAAnderson - SNRI, 2020 Furu - Venlafaxine, 2015 Reis - SNRI (Controls unexposed, NOS), 2010 3 Tags Adjustment   - Yes  - Yes 1.39[0.86; 2.25]7,7374,1140%NAAnderson - SNRI, 2020 Furu - Venlafaxine, 2015 Reis - SNRI (Controls unexposed, NOS), 2010 3 Monotherapy   - SNRI only  - SNRI only 1.39[0.86; 2.25]7,7374,1140%NAAnderson - SNRI, 2020 Furu - Venlafaxine, 2015 Reis - SNRI (Controls unexposed, NOS), 2010 3 All studiesAll studies 1.39[0.86; 2.25]7,7374,1140%NAAnderson - SNRI, 2020 Furu - Venlafaxine, 2015 Reis - SNRI (Controls unexposed, NOS), 2010 30.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 11693

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.39[0.86; 2.25]7,7374,1140%NAAnderson - SNRI, 2020 Furu - Venlafaxine, 2015 Reis - SNRI (Controls unexposed, NOS), 2010 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.82[0.29; 2.31]151,351 -NAReis - SNRI (Controls exposed to TCA), 2010 10.510.01.0